Literature DB >> 34144027

Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity.

Cheri Z Liu1, Marco Mottinelli2, Hilary E Nicholson1, Bridget M McVeigh1, Neelum K Wong1, Christopher R McCurdy2, Wayne D Bowen3.   

Abstract

Sigma-2 receptor/transmembrane protein 97 (TMEM97) is upregulated in cancer cells compared to normal cells. Traditional sigma-2 receptor agonists induce apoptosis and autophagy, making them of interest in cancer therapy. Recently, we reported a novel metabolically stimulative function of the sigma-2 receptor, showing increased 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and stimulation of glycolytic hallmarks. 6-Substituted analogs of the canonical sigma-2 receptor antagonist, 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), produce both metabolically stimulative and cytotoxic effects. Here, we compare the activities of two related compounds: 6-amino-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (CM571), the 6-amino derivative of SN79, which binds with high affinity to both sigma-1 and sigma-2 receptors, and 1,3-bis(3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)thiourea (MAM03055A), a homo-bivalent dimer of CM571. MAM03055A resulted from the degradation of 3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one (CM572), the cytotoxic 6-isothiocyanato SN79 derivative. MAM03055A exhibited high affinity and strong preference for sigma-2 receptors (sigma-1 Ki = 3371 nM; sigma-2 receptor Ki = 55.9 nM). Functionally, MAM03055A treatment potently induced cell death in SK-N-SH neuroblastoma, MDA-MB-231 breast, and both SW48 and SW480 colorectal cancer cell lines, causing proapoptotic BH3 interacting-domain death agonist (BID) cleavage in SK-N-SH cells. Conversely, CM571 induced metabolic stimulation. CM571 bound reversibly to both receptors, while MAM03055A bound pseudo-irreversibly to sigma-2 receptors and caused residual cytotoxic activity after acute exposure and removal of the compound from the media. Interestingly, MAM03055A induced a time-dependent loss of sigma-2 receptor/TMEM97 protein from cells, whereas monomer CM571 had no effect on receptor levels. These results suggest that monovalent and bivalent sigma-2 receptor ligands in this series interact differently with the receptor, thus resulting in divergent effects.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  1,3-bis(3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)thiourea; 1,3-di-o-tolylguanidine; 1’-(4-(1-(4-fluorophenyl)-1H-indol-3-yl)butyl)-3H-spiro(2-benzofuran-1,4′-piperidine); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one; 6-acetyl-3-(4-(4-(2-amino-4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one; 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one; 6-amino-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one; Apoptosis; CM571; CM572; CM764; Cancer metabolism; DTG; MAM03055A; MTT; Neuroblastoma; Progesterone receptor membrane component 1; SN79; Sigma-2 receptor; Siramesine; TMEM97

Mesh:

Substances:

Year:  2021        PMID: 34144027      PMCID: PMC8736263          DOI: 10.1016/j.ejphar.2021.174263

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   5.195


  37 in total

1.  Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity.

Authors:  Hilary Nicholson; Anthony Comeau; Christophe Mesangeau; Christopher R McCurdy; Wayne D Bowen
Journal:  J Pharmacol Exp Ther       Date:  2015-06-01       Impact factor: 4.030

2.  Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands.

Authors:  Giuseppe Romeo; Orazio Prezzavento; Sebastiano Intagliata; Valeria Pittalà; Maria N Modica; Agostino Marrazzo; Rita Turnaturi; Carmela Parenti; Santina Chiechio; Emanuela Arena; Agata Campisi; Giovanni Sposito; Loredana Salerno
Journal:  Eur J Med Chem       Date:  2019-04-21       Impact factor: 6.514

3.  Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines.

Authors:  Keith W Crawford; Wayne D Bowen
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

4.  A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain.

Authors:  S B Hellewell; W D Bowen
Journal:  Brain Res       Date:  1990-09-17       Impact factor: 3.252

5.  Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity.

Authors:  James J Sahn; Timothy R Hodges; Jessica Z Chan; Stephen F Martin
Journal:  ACS Med Chem Lett       Date:  2017-03-21       Impact factor: 4.345

Review 6.  Triple-negative breast cancer--current status and future directions.

Authors:  O Gluz; C Liedtke; N Gottschalk; L Pusztai; U Nitz; N Harbeck
Journal:  Ann Oncol       Date:  2009-11-09       Impact factor: 32.976

7.  Sigma-2 ligands induce tumour cell death by multiple signalling pathways.

Authors:  C Zeng; J Rothfuss; J Zhang; W Chu; S Vangveravong; Z Tu; F Pan; K C Chang; R Hotchkiss; R H Mach
Journal:  Br J Cancer       Date:  2012-01-17       Impact factor: 7.640

8.  Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.

Authors:  Nicholas J Izzo; Jinbin Xu; Chenbo Zeng; Molly J Kirk; Kelsie Mozzoni; Colleen Silky; Courtney Rehak; Raymond Yurko; Gary Look; Gilbert Rishton; Hank Safferstein; Carlos Cruchaga; Alison Goate; Michael A Cahill; Ottavio Arancio; Robert H Mach; Rolf Craven; Elizabeth Head; Harry LeVine; Tara L Spires-Jones; Susan M Catalano
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

9.  A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Authors:  Michael Grundman; Roger Morgan; Jason D Lickliter; Lon S Schneider; Steven DeKosky; Nicholas J Izzo; Robert Guttendorf; Michelle Higgin; Julie Pribyl; Kelsie Mozzoni; Hank Safferstein; Susan M Catalano
Journal:  Alzheimers Dement (N Y)       Date:  2019-01-23

10.  The Sigma-2 receptor / transmembrane protein 97 (σ2R/TMEM97) modulator JVW-1034 reduces heavy alcohol drinking and associated pain states in male mice.

Authors:  Sema G Quadir; Sean M Tanino; Christian D Rohl; James J Sahn; Emily J Yao; Luíza Dos Reis Cruz; Pietro Cottone; Stephen F Martin; Valentina Sabino
Journal:  Neuropharmacology       Date:  2020-11-20       Impact factor: 5.250

View more
  1 in total

1.  TMEM97 is transcriptionally activated by YY1 and promotes colorectal cancer progression via the GSK-3β/β-catenin signaling pathway.

Authors:  Dong Mao; Xiaowei Zhang; Zhaoping Wang; Guannan Xu; Yun Zhang
Journal:  Hum Cell       Date:  2022-07-30       Impact factor: 4.374

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.